Hematología y Hemoterapia

Resultados: 408
Tipo Título / Nombre Autor(es) Año
Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Relapsed/Refractory Acute Myeloid Leukemia (AML) Zeidner J, Lin T, Vigil C, Dalovisio A, Wang E, Yair Levy M, et al 2018
Role of Measurable Residual Disease (MRD) in Redefining Complete Response (CR) in Elderly Patients with Acute Myeloid Leukemia (AML): Results from the Pethema-Flugaza Phase III Clinical Trial Paiva B, Martínez Cuadrón D, Bergua Burgués J, Vives S, Lorenzo Algarra J, Tormo M, et al 2018
Precision Medicine Test Is Similar but Faster Than Conventional Cytogenetics Predicting Response in AML Patients and Provides Alternative Treatments Ballesteros J, Martínez Cuadrón D, Martínez López J, Bergua Burgués J, Trmo M, Serrano J, et al 2018
Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia Felipe Grajales A, Chavez Julio C, Turba EP, Nodzon L, Pérez Leal F, Sandoval Sus J, et al 2018
Long Term Survival Analysis of Multiple Myeloma Patients Receiving Induction Therapy+ Autologous STEM CELL Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction Therapy Cáceres S, Cardesa R, Cabrera C, Bañas MH, Ibañez F, Prieto J, et al 2018
Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols Genesca E, Morgades M, Montesinos P, Barba P, Gil C, Guàrdia R, et al 2018
Analysis of three salvage treatment regimens after relapsed/refractory acute myeloi leukemia (AML) (FLAG-Ida, FLAGO-IDA and PLERIFLAG) Bergua J, Martínez Cuadrón D, Boluda B, Martínez P, Rodríguez Veiga R, Esteve J, et al 2018
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, et al 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, et al 2018